{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:47:37Z","timestamp":1794278857305,"version":"4.9.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007174","name":"Pfizer Inc Boulder","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007174","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ijid.2021.10.022","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T02:59:39Z","timestamp":1634612379000},"page":"279-281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Antimicrobial activities of ceftazidime\/avibactam, ceftolozane\/tazobactam, imipenem\/relebactam, meropenem\/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections"],"prefix":"10.1016","volume":"113","author":[{"given":"Helio S.","family":"Sader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard R.","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ijid.2021.10.022_bib0001","doi-asserted-by":"crossref","first-page":"e95042","DOI":"10.1371\/journal.pone.0095042","article-title":"Gram negative wound infection in hospitalised adult burn patients\u2013systematic review and metanalysis","volume":"9","author":"Azzopardi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2021.10.022_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2019.07.002","article-title":"Antibiotic resistance in Pseudomonas aeruginosa - Mechanisms, epidemiology and evolution","volume":"44","author":"Botelho","year":"2019","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.ijid.2021.10.022_bib0003","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: eleventh edition M07","year":"2018"},{"issue":"2","key":"10.1016\/j.ijid.2021.10.022_bib0004","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/QCO.0000000000000050","article-title":"Novel antibiotic treatment for skin and soft tissue infection","volume":"27","author":"Dryden","year":"2014","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ijid.2021.10.022_bib0005","unstructured":"EUCAST. Breakpoint tables for interpretation of MICs and zone diameters. Version 11.0, January 2021. January 1, 2021 ed: European Committee on Antimicrobial Susceptibility Testing; 2021."},{"issue":"Supplement 1","key":"10.1016\/j.ijid.2021.10.022_bib0006","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/ofid\/ofy346","article-title":"Global Surveillance of antimicrobial resistance: 20 years of experience with the SENTRY Program","volume":"6","author":"Fuhrmeister","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"10.1016\/j.ijid.2021.10.022_bib0007","doi-asserted-by":"crossref","first-page":"e00031","DOI":"10.1128\/CMR.00031-19","article-title":"Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections","volume":"32","author":"Horcajada","year":"2019","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"10.1016\/j.ijid.2021.10.022_bib0008","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/QCO.0000000000000677","article-title":"Current choices of antibiotic treatment for Pseudomonas aeruginosa infections","volume":"33","author":"Ibrahim","year":"2020","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ijid.2021.10.022_bib0009","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft-tissue infections: 2014 Update by the Infectious Diseases Society of America","volume":"5","author":"Stevens","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.ijid.2021.10.022_bib0010","doi-asserted-by":"crossref","first-page":"e00115","DOI":"10.1128\/CMR.00115-20","article-title":"New beta-lactam-beta-lactamase inhibitor combinations","volume":"34","author":"Yahav","year":"2020","journal-title":"Clin Microbiol Rev"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221008092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221008092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:07:40Z","timestamp":1761120460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971221008092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":10,"alternative-id":["S1201971221008092"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2021.10.022","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimicrobial activities of ceftazidime\/avibactam, ceftolozane\/tazobactam, imipenem\/relebactam, meropenem\/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2021.10.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}